Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alexis Q. Dean"'
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, name
Externí odkaz:
https://doaj.org/article/0ea1fe9accbc4cd4ace5cfd15f8eba42
Autor:
Alexis Q Dean, Charles B Stauft, Julianne D Twomey, Joshua Tan, Luca Varani, Tony T Wang, Baolin Zhang
Publikováno v:
Antibody Therapeutics. 6:49-58
BackgroundNeutralising antibodies against SARS-CoV-2 are a vital component in the fight against COVID-19 pandemic, having the potential of both therapeutic and prophylactic applications. Bispecific antibodies (BsAbs) against SARS-CoV-2 are particular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f01d08c6b9049917eaffbba29faf9bc2
https://doi.org/10.1093/abt/tbac032
https://doi.org/10.1093/abt/tbac032
Publikováno v:
Drug Discovery Today
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by interacting with membrane-bound angiotensin-converting enzyme 2 (ACE2), a vital element in the renin-angiotensin system (RAS), which regulates blood pressure,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a36d0a5d240d9e6576289b638c109dea
http://europepmc.org/articles/PMC8049177
http://europepmc.org/articles/PMC8049177
Publikováno v:
Drug Resistance Updates
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eca0a498a9c1d11430a2e887b9983ed
https://doi.org/10.1016/j.drup.2020.100733
https://doi.org/10.1016/j.drup.2020.100733